Rabbit KCNH2 Polyclonal Antibody | anti-KCNH2 antibody
Anti-KCNH2 Antibody
Direct ELISA: 0.1-0.5ug/ml
Background: KCNH2, also known as HERG or KV11.1, encodes the pore-forming subunit of a rapidly activating-delayed rectifier potassium channel. It is mapped to 7q36.1. KCNH2 forms the major portion of one of the ion channel proteins (the 'rapid' delayed rectifier current (IKr)) that conducts potassium (K+) ions out of the muscle cells of the heart (cardiac myocytes), and this current is critical in correctly timing the return to the resting state (repolarization) of the cell membrane during the cardiac action potential. What’s more, KCNH2 channels show gating properties consistent with many of the outwardly rectifying potassium channels, but they also have an inactivation mechanism that attenuates efflux during depolarization.
NCBI and Uniprot Product Information
NCBI Description
This gene encodes a voltage-activated potassium channel belonging to the eag family. It shares sequence similarity with the Drosophila ether-a-go-go (eag) gene. Mutations in this gene can cause long QT syndrome type 2 (LQT2). Transcript variants encoding distinct isoforms have been identified. [provided by RefSeq, Jul 2008]
Uniprot Description
Kv11.1: the ether-a-go-go related gene is a pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel is associated with cardiac arrhythmias and rhythmic excitability of the pituitary. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). The potassium channel is probably composed of a homo- or heterotetrameric complex of pore-forming alpha subunits that can associate with modulating beta subunits. Heteromultimer with Kv11.2 and Kv11.3. Interacts with ALG10B. Heteromultimer with KCNE1 and KCNE2. Defects in Kv11.1 are the cause of long QT syndrome type 2 (LQT2), a heart disorder characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to exercise or emotional stress. Deafness is often associated with LQT2. Defects in Kv11.1 are the cause of short QT syndrome type 1 (SQT1), a heart disorder characterized by idiopathic persistently and uniformly short QT interval on ECG in the absence of structural heart disease in affected individuals. They cause syncope and sudden death. Four isoforms of the human protein are produced by alternative splicing. Isoform 3 has no channel activity by itself, but modulates channel characteristics when associated with isoform 1.
Protein type: Membrane protein, multi-pass; Membrane protein, integral; Channel, potassium; Motility/polarity/chemotaxis
Chromosomal Location of Human Ortholog: 7q36.1
Cellular Component: voltage-gated potassium channel complex; cell surface; cytoplasm; plasma membrane; nuclear envelope
Molecular Function: identical protein binding; protein binding; voltage-gated potassium channel activity; protein homodimerization activity; delayed rectifier potassium channel activity; ubiquitin protein ligase binding; inward rectifier potassium channel activity; two-component sensor activity
Biological Process: synaptic transmission; regulation of membrane potential; two-component signal transduction system (phosphorelay); regulation of the rate of heart contraction by hormone; potassium ion homeostasis; cardiac muscle contraction
Disease: Long Qt Syndrome 2; Short Qt Syndrome 1
Research Articles on KCNH2
Similar Products
Product Notes
The KCNH2 kcnh2 (Catalog #AAA1752449) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The Anti-KCNH2 Antibody reacts with Human, Mouse, Rat and may cross-react with other species as described in the data sheet. AAA Biotech's KCNH2 can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB), Direct ELISA (EIA). WB: 0.1-0.5ug/ml Direct ELISA: 0.1-0.5ug/ml. Researchers should empirically determine the suitability of the KCNH2 kcnh2 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "KCNH2, Polyclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
